Allt inom Other Corporate Information
Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell®
- Nanexa’s atomic layer deposition (ALD)‑based PharmaShell® platform enables an unprecedented pharmacokinetic profile for semaglutide, also supporting the potential for once‑quarterly administration.
- New preclinical data shows ultra‑long release indicating an exceptionally smooth plasma concentration profile for repeated quarterly dosing in human PK simulations
- The results strengthen Nanexa’s position in the rapidly evolving metabolic disease treatment landscape and reinforce the company’s ability to secure new commercial collaborations.
Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)
The Nomination Committee for the Annual General Meeting 2026 in Nanexa AB (publ) has been appointed.